Energy status and metabolism in skeletal muscle of nine patients with peripheral arterial disease and suffering from intermittent claudication were evaluated using 3'phosphorus magnetic resonance spectroscopy (MRS) before and after treatment for 3 months with propionyh-carnitine (PLC;2 g/day p.o.), Maximum walking distance (MWD) was assessed on a standard treadmill (4 km/h, zero incline). For the group as a whole 3lp MRS results did not change significantly with PLC. Although MWD increased by a mean of 36%, this change did not reach significance. However, when these variables were assessed with respect to the change in MWD, there were significant differences between those who increased MWD by > 30% (responders, R;n = 5) and those who did not (nonresponders, NR; n = 4). Compared with pretreatment values, during exercise the decrease in muscle pH in R relative to the decrease in phosphocreatine was less after PLC (p = 0.04). After exercise there was a significant inverse correlation between the changes in recovery half-time (t!) for phosphocreatine and in MWD (r= -0.91, p =0.01). With PLC, V m • x increased in R (p = 0.04), but not in NR. For the patient group as a whole, the changes in V m a x and MWD correlated positively (f= 0.90, P = 0.01). This study helps to identify the changes in muscle metabolism that correlate with changes in exercise performance, and may accompany treatment with PLC.
Introduction
We have previously shown that marked metabolic abnormalities are present in skeletal muscle of peripheral arterial disease (PAD) patients: glycolytic adenosine triphosphate (ATP) synthesis and intracellular acidification are increased while oxidative ATP synthesis is reduced.l-' Free carnitine and acylcarnitine content. as well as carnitine acetyltransferase activity, may be reduced in ischaemic muscle.' There is a reduction in blood flow and slow washout of lactic acid from muscle. I However. the relationship between the metabolic abnormalities and the well-established reduced exercise tolerance of the patients has not been investigated.
In the present study. we have compared the results from 31p magnetic resonance spectroscopy (MRS) studies of patients suffering from PAD with measurements of maximum walking distance (MWD) before and after 3 PAD.4-6 probably by increasing oxidative metabolism in muscle. PLC is also able to restore normal levels of carnitine and its esters in skeletal muscle. ' The results from the present study have been used to characterize the alterations in the bioenergetic state of the muscle that accompany the changes in exercise tolerance.
Methods

Subjects
Studies were performed on seven male and two female patients aged 43-84 years (mean 71 years) who had experienced calf claudication due to angiographically confirmed PAD for at least I year. Maximum walking distance (the distance at which a patient stopped walking because of pain) was established on a treadmill (4 km/h, zero incline) and had to be between 50 and 200 m. Anklelbrachial pressure indices (ABI) are shown in Table I . To qualify for the study. a patient had to show a fall in ankle pressure of at least 20 mmHg after I min on the treadmill (4 km/h, 10% incline). Only one patient had never smoked; another was still smoking. but the remainder had all relinquished the habit. Two patients had type II diabetes mellitus and six were on treatment for hypertension (none with l3-blocking agents). Results before and after 3 months' treatment with PLC (2 g/day p.o.) were compared.
All SUbjects gave informed consent according to a protocol approved by the local hospital ethics committee. 
MRS
The study used a 2.0 T superconducting magnet (Oxford Magnet Technology, Eynsham, Oxford, UK) interfaced to a Bruker spectrometer (Bruker, Coventry, UK). Subjects lay with the affected calf overlying a 6 cm diameter surface coil. Spectra were acquired using a 2 s interpulse delay at rest (64 scans) and during exercise and recovery. The muscle was exercised by plantar flexion at 0.5 Hz, lifting a weight of 5% of lean body mass (calculated from body weight and skinfold thickness7) through a distance of 7 cm. The patients exercised until stopped by claudication pain. If the patient could tolerate an increased work load after two 32-scan spectra had been acquired, the weight was increased to 10% of the lean body mass, and after four spectra the weight was incremented by 2% of the lean body mass for each subsequent spectral acquisition (the time for acquisition and storage of each spectrum was 1.25 min). In six patients we were able to increase the load to 10% after two spectral acquisitions and in two of these two additional increments were applied. Each patient repeated the same protocol for the post-treatment study. Data were collected for 13 minutes during recovery (four eight-scan spectra followed by four of 16 scans, three of 32 scans and two of 64 scans).
Relative concentrations of inorganic phosphate (Pi), phosphocreatine (PCr) and ATP were obtained by a timedomain fitting routine (VARPRO, R. de Beer, Delft, Holland) and were corrected for magnetic saturation. Absolute concentrations were obtained by assuming that the concentration of ATP ([ATP» in normal muscle is 8.2 mmol/litre of muscle water." Previously published data on muscle biopsies of PAD patients showed a decrease in [ATPj at rest of about 16%,9.10 and the calculation of metabolite concentrations in the patients' muscles was Free cytosolic adenosine diphosphate concentration ([ADP]) was calculated from pH and [PCr] using a creatine kinase equilibrium constant (K eq ) of 1.66 x 109/(molll)11 and assuming a normal total creatine content of 42.5 mmol/litre of intracellular water as":
For statistical purposes, the phosphorylation potential was expressed as its reciprocal, ( 
Presentation and statistics
Results are presented as means ± I SO. Statistical significance between data collected pretreatment and after 3 months on PLC was determined by the Wilcoxon signedrank test. Patients were divided into two groups, responders and nonresponders, depending on the change in MWD after PLC administration. Significance between those who had a positive response in MWD (R, increase> 30%5) and those who did not respond (NR) was determined by Mann-Whitney U test. Correlations were made using Spearman's correlation coefficient.
Results
The MWD of the patients on the treadmill correlated positively with the duration of exercise in the MRS studies (r =0,49, p =0.04; Figure I ), suggesting that the two types of exercise were comparable metabolically, since the duration in each was dependent on the pain and fatigue experienced by the patient. MWD also correlated negatively with the calculated ADP concentration in resting muscle (r = -0.77, P = 0.03), that is, those who walked furthest had the lowest ADP concentrations at rest. Before the start of PLC the patients' MWD on the treadmill was 158 ± 46 m (72-226 m, Table I Table I . After 3 months of treatment the mean MWD of the patients increased by 36% over the pretreatment value to 216 ±97 m, although this did not reach significance (p = 0.09). For the group as a whole, the mean values for magnet exercise duration and the MRS findings shown in Table 2 were not significantly altered by PLC.
. Results from the patients who responded to treatment (R, 11 = 5) and those who did not (NR, 11 = 4), were then compared. An increase of > 30% in MWD was required for inclusion in group R in order to reduce the possibility that changes in MWD were simply due to a placebo effect; however, the actual range in the increase in MWD in R was 46-95% (see Table I and Discussion). There were no significant differences between Rand NR in any of the MRS values before PLC. After PLC, all five patients in the R group showed less of a pH change in exercise for a given change in [PCr] when compared with the pre-PLC value, indicating either that glycolytic activity was reduced or that proton efflux from the muscle was increased (see Discussion). This relationship is shown in Table I as the slope of the plot of pH versus log[PCr/(PCr + Pi)]; the slope decreased by 19 ± 5% in R after treatment (p =0.04). The measurement could not be made in two of the NR patients because depletion of PCr during exercise was not great enough for reliable measurement. In the remaining two patients, however, the slope increased following treatment.
There was evidence from the recovery data that oxidative function increased in some patients with treatment. As shown in Table I Figure 2 for the half-time of PCr/(PCr + Pi), as this also takes account of Pi recovery (r =-0.94, p =0.008).
A similar relationship was found for half-time for ADP recovery. In the R group there was a decrease in four patients and no change in one (Table I) , while there was an increase in all four of the NR group (p =0.0 I, Table I ).
As with PCr, the percentage change in MWD correlated negatively with the percentage change in half-time (r =-0.85, P =0.02). Before treatment the Vmax for oxidative ATP synthesis was not significantly different between Rand NR (Table I) , but it increased by a mean of 33 ±25% in R and decreased by 32 ± 23% in NR (p = 0.01). The changes in V max correlated positively with the changes in MWD (r = 0.90, p = 0.02; Figure 2 ).
Cholesterol, HDL-cholesterol and triglyceride levels were measured in all patients before and after treatment. There were no significant differences in levels between R and NR, and no significant changes were induced by treat-ment. In the R group, three patients reported symptomatic improvement and two no change. In NR, three thought there was slight improvement and one thought there was no change. In each group, one patient reported an increase in daily activity during the result of the study.
Oxidative ATP synthesis is impaired in skeletal muscle of patients suffering from PAD. The reduction in blood flow leads to an inadequate supply of oxygen for ATP synthesis, and muscle pH recovers very slowly after exercise. Compared with normal controls, the duration of exercise is decreased, the postexercise recovery of PCr, ADP and intracellular pH are slow, and the maximum rate of ATP synthesis is low. J.2 The decrease in oxygen availability may not be the only factor limiting oxidative energy production. Low muscle camitine and acylcamitines have been reported in patients with PAD. 3 Camitine is a cofactor involved in transporting fatty acids, which are used as substrates for oxidative metabolism, across the mitochrondrial membrane. It also helps to regulate the ratio of acetylcoenzyme Nfree coenzyme A (acetyICoNCoA), thereby affecting pyruvate dehydrogenase activity and the oxidative metabolism of glucose. It has been found that camitine or PLC administration can increase the MWD of PAD patients, reduce postexercise lactate concentrations in blood and lead to a faster recovery of the lactate: pyruvate ratio.4-6,'4 The increase in MWD of 36% in the present study is similar to increases of 45% and 39% found in much larger studies.t'" There was no effect on blood flow obtained by impedance plethysmography or in the anklelbrachial systolic blood pressure ratio as measured by Doppler ultrasound." In our study, as in others, not all claudicant patients improved on treatment. Although the exact biochemical or physiological basis for a difference in response is not yet clear (possible effects of training and of changes in exercise and postexercise blood flow cannot be ruled out), recently published results showed that claudicant patients who responded to intravenous L-carnitine administration with increased walking capacity had higher plasma acetylcarnitine at rest than did control subjects and patients who did not increase walking distance with treatment."
The changes we observed in MWD over the 3-month period were accompanied by changes in calf muscle metabolism as observed by MRS. The MRS findings in R (decrease in the half-times of recovery for PCr and ADP, increase in V max for oxidative ATP synthesis and decrease in the slope of pH versus 10g[PCr/(PCr + Pi)]) were consistent with changes in both anaerobic and oxidative metabolism of the muscle and with more normal muscle function.':" PCr and ADP recovery times are both sensitive indicators of oxidative function, while the calculated V max for mitochondrial ATP synthesis is a measure of the overall oxidative capacity (these are derived from postexercise recovery data, and the recovery period relies entirely on oxidative metabolism). PCr and ADP recovery rates and V max are low in conditions where mitochondrial ATP synthesis is IOW. 12 , 16 , 17 Thus, increased MWD was associated with improved oxidative function. Although the number of patients investigated was small, the results suggest that those who responded tended to be the patients whose walking distance and metabolism were the most compromised. The longest pretreatment recovery times for PCr and ADP and the lowest Vmax values were all in the responder group. This is consistent with the findings of Brevetti et al" who also found that patients with lower walking capacity were those who increased the time to initial claudication pain on intravenous administration of L-carnitine.
The decrease in pH relative to PCr depletion in those patients who increased MWD suggests a decrease in lactic acid production. In patients with claudication, glycolysis (and, therefore, lactate production) is increased and proton efflux is decreased.' Our findings are consistent, therefore, with a decrease in glycolytic rate or with increased proton efflux. The current data do not discriminate between the two possibilities, but previous findings show that L-carnitine reduces blood lactate levels after exercise," which is consistent with a reduction in glycolytic rate. Thus, our results suggest that there was an increase in oxidative activity and a decrease in anaerobic glycolysis in those patients who improved their MWD.
It is interesting to note that initial MWD correlated negatively with the ADP concentration in resting muscle. That is, patients with the most normal concentrations walked the furthest. ADP in resting muscle is elevated in mitochondrial myopathy, in which oxidative metabolism is compromised.
PLC mayor may not be responsible for changes in MWD, but this does not affect the finding that measurable differences in muscle metabolism are associated with changes in treadmill exercise performance. Although treadmill walking distance has often been dismissed in the past as an unreliable, poorly reproducible measure of claudication severity, this study shows that it correlates well with muscle bioenergetics.
